As part of its longstanding commitment to Africa, Johnson & Johnson today announced the launch of the Africa Innovation Challenge, an initiative to support Africa’s vibrant and growing innovation ecosystem and to help develop important and locally sustainable consumer health solutions. The challenge is the latest initiative in the company’s comprehensive approach to advancing health and innovation worldwide. The Johnson & Johnson Family of Companies’ presence in Africa dates back more than 80 years and includes business operations, public health programs and corporate citizenship.
“Through the Africa Innovation Challenge, we have the opportunity to support the continent’s top entrepreneurs through mentorship and other resources, and by working together with local talent, to bring forward new solutions to local health care challenges,” said Paul Stoffels, M.D., Executive Vice President and Chief Scientific Officer, Johnson & Johnson.
To view the multimedia release go to:
http://www.multivu.com/players/English/7967451-jnj-africa-innovation-challenge/
Don’t trust us, trust Science: Abbott is among the best science-based companies to work for in the world.
For the 13th consecutive year, the journal Science today recognized Abbott on its Top Employers list, evaluated on 23 characteristics including financial strength, easy adaptation to change and a having a research-driven environment.
”Abbott is unique in that we’ve been adding to our reservoir of scientific knowledge for 128 years,“ said John Frels, Ph.D., chair of Abbott’s Scientific Governing Board, which oversees the company’s senior scientific career track. ”We strive to bring in the best and brightest scientists and engineers to work on some of the biggest problems in healthcare today. This helps us to create new, breakthrough innovations that change people’s lives.“
To view the multimedia release go to:
http://www.multivu.com/players/English/7962251-science-names-abbott-2016-top-employer/
The Astana Economic Forum is an annual event held in Astana, the capital of the Republic of Kazakhstan, which brings together representatives from the world’s economic community, current and former heads of states, Nobel Prize laureates, outstanding figures from the scientific world, and businessmen. The Forum is best known as a platform for international dialogue that enables constructive discussion of economic development issues concerning both Central Asia and the entire world in relation to changes witnessed in the global economy.
This year the Astana Economic Forum 2016 was held on May 25-26 in Astana, Kazakhstan under the theme “New economic reality: diversification, innovation and knowledge economy”. The agenda of the Forum traditionally included the most topical issues on economic development.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7872751-recommendations-astana-economic-forum/
The website www.MyPerfectDish.eu aims to help people with Parkinson’s, their relatives and caregivers in taking care of their nutritional requirements in order to help them enjoy tasty food that meets their dietary needs.
The website is endorsed by the European Parkinson’s Disease Association (EPDA) and sponsored by Zambon, and has been designed as an easy-to-use scientific information tool so people living with Parkinson’s can be confident that what they are reading is reliable.
“As the only European Parkinson’s umbrella organisation, the EPDA is very proud to endorse this project, which is based on solid scientific and medical grounds,” explains EPDA president Knut-Johan Onarheim. “A balanced and varied diet is important for everyone but it is even more important for people living with Parkinson’s disease because the right food intake can improve their quality of life as well as the effects of therapeutic treatments”.
“Zambon is very proud of having supported this project, which will help people with Parkinson’s and all those involved in the management of the disease. We are strongly committed to drive research and develop solutions to help patients in all their needs“. states Elena Zambon, President of Zambon.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7864251-parkinsons-diet-online-resource/
The foetus moves its mouth in an exaggerated manner when it hears a human voice. This occurs from the 16th week of pregnancy (with a foetus of 11cm) and only when the voice reaches it through an intravaginal device developed for this purpose. This is one of the conclusions of the study presented by Dr. Álex García-Faura, the Scientific Director of the Institut Marquès, at the 25th European Congress of Perinatal Medicine held in Maastricht (Netherlands).
The study finds that babies hear practically no external noise and only react when sound reaches them through the vagina, which confirms that they hardly hear voices through the mother’s abdomen. Their reactions were studied using Babypod®, a small device that is inserted into the vagina like a tampon and is connected to a mobile phone, enabling the voice of the mother or anyone else to reach the foetus.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7859951-institut-marques-babies-react-mother-voice/
As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy.
Dr. Ohsumi was honored today during an event at the 2016 BIO International Convention in San Francisco. A video of his acceptance comments can be viewed here.
“Dr. Ohsumi’s curiosity led him to become the first person in the world to determine the molecular mechanism and regulation of autophagy, shedding light on one of the most basic functions of all living cells,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. “Dr. Ohsumi’s discoveries hold promise for better understanding, preventing and treating many diseases. It is with great pleasure that we celebrate his contributions, which remind us of the innovative spirit Dr. Paul brought to the lab every day.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7856351-2016-dr-paul-janssen-award-ohsumi/
A decade ago Turtle Beach Corporation (NASDAQ: HEAR), a leading audio technology company for over 40 years, pioneered the console gaming headset category and is set to do so again in 2016 with its revolutionary Turtle Beach® Elite Pro Tournament Gaming Headset, Elite Pro Tactical Audio Controller (T.A.C.) and Elite Pro accessories designed for competitive gamers, which establishes a new standard for eSports gaming audio performance and comfort. Turtle Beach’s “Elite” series products represent the highest level in audio and build quality, and the all-new Elite Pro Headset, T.A.C. and Elite Pro accessories are the Company’s all-new line of competitive gaming audio gear created to meet the demands of today’s professional and aspiring pro teams and players.
The Elite Pro Headset’s journey began in 2013. Seeing the consistent growth and popularity of eSports, Turtle Beach launched a comprehensive scientific research program to deeply examine the needs of professional and hardcore gamers as it pertained to game audio, communicating with teammates, and overall comfort. The result is the all-new Elite Pro Tournament Gaming Headset – a ground-up redesign of the competitive gaming headset that brings to market multiple first-and-only innovations in the core mechanics of headset design, weight and fit. Not only does the Elite Pro Headset provide Turtle Beach’s best-in-class game audio and chat performance, but also delivers groundbreaking comfort-driven technologies, including the ComforTec® Fit System with multiple adjustment points for a truly personalized headset fit and feel, Aerofit® Ear Cushions that stay cool in the heat of battle, and Turtle Beach’s all-new patented ProSpecs® Glasses Relief System that finally makes wearing a gaming headset comfortable for players who wear glasses.
To view the multimedia release go to:
http://www.multivu.com/players/English/7537953-turtle-beach-optic-gaming-elite-pro/
After his wife of 54 years died in 2006, Chuck Swartwout decided there had to be more to life than merely the time spent on earth.
This realization motivated him to take a long analytical look at the afterlife, which he believes we will all enter after death. Using his training in the scientific method, Swartwout researched and published You Don’t Die – You Just Change Channels! which he describes as a ‘common sense’ approach to prove the existence of an afterlife.http://www.chuckswartwout.com/ Media Contact: For a review copy of You Don’t Die – You Just Change Channels! or to arrange an interview with Chuck Swartwout, contact Scott Lorenz of Westwind Communications Book Marketing at scottlorenz@westwindcos.com or by phone at 734-667-2090 http://www.book-marketing-expert.com Inspirational
Through thousands of hours meeting with women from Dallas to Taipei, Sao Paulo to Paris, Neutrogena® uncovered a universal truth – women are stepping back to examine what’s possible in their lives so they can pursue their dreams. Always on a mission to create, innovate, and rethink what’s possible in skincare, Neutrogena® identified this shared value and was inspired to launch its first-ever global campaign: “Neutrogena. See What’s Possible.™”
“Neutrogena® started as a dream, and through scientific discovery, creative thinking and the resilience to defy expectations without any compromises, a brand was born,” said Alicia Sontag, President, Beauty Care, Johnson & Johnson Consumer Inc. “We support women around the world and are proud to help them put their best face forward as they pursue their own dreams – big or small.”
The “Neutrogena. See What’s Possible™” campaign will debut with a commercial voiced by Brand Ambassador and creative consultant Kerry Washington which features real women following their passions. The empowering video brings to life the brand’s point of view on beauty – what really makes a woman beautiful is the ability to look in the mirror and know that anything is possible. In addition, educational and inspiring digital content designed to encourage her along her journey will be leveraged through social platforms in over 27 countries around the world, making this the largest digitally-driven campaign the brand has ever executed.
To view the multimedia release go to:
http://www.multivu.com/players/English/7770451-neutrogena-see-what-s-possible/
International research led by University College London (UCL) as part of the ‘Cities Changing Diabetes’ partnership programme challenges current scientific understanding of the rapid rise of diabetes in cities. The findings suggest that in cities around the world, social and cultural factors play a far more important role in the spread of the epidemic than previously thought.
More than two thirds of the world’s 400 million people with diabetes live in urban areas.1,2 The year-long study for Cities Changing Diabetes, a unique public-private-academic partnership, sought to better understand what makes people vulnerable to type 2 diabetes in cities in order to inform solutions for one of the most pressing modern-day public health challenges. To explore this complex issue, more than 550 interviews were undertaken with at-risk and diagnosed people in five major cities – Copenhagen, Houston, Mexico City, Shanghai and Tianjin.
“By largely focusing on biomedical risk factors for diabetes, traditional research has not adequately accounted for the impact of social and cultural drivers of disease,” says David Napier, Professor of Medical Anthropology, UCL. “Our pioneering research will enable cities worldwide to help populations adapt to lifestyles that make them less vulnerable to diabetes.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7690951-study-rethink-rise-diabetes-in-cities/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
